Functional inactivation of endogenous MDM2 and CHIP by HSP90 causes aberrant stabilization of mutant p53 in human cancer cells

Molecular Cancer Research

Volumn 9, Issue 5, 2011, Pages 577-588

  Li, Dun ^a   Marchenko, Natalia D ^a   Schulz, Ramona ^b   Fischer, Victoria ^a   Velasco Hernandez, Talia ^a   Talos, Flaminia ^a   Moll, Ute M ^a,b  

^a STONY BROOK UNIVERSITY   (United States)

^b UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOXY TERMINUS OF HSP 70 INTERACTING PROTEIN; HEAT SHOCK PROTEIN 90; HEAT SHOCK TRANSCRIPTION FACTOR 1; PROTEIN MDM2; PROTEIN P53; TANESPIMYCIN; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER INHIBITION; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; HUMAN; HUMAN CELL; MISSENSE MUTATION; MUTANT; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; RNA INTERFERENCE; TRANSCRIPTION REGULATION; UBIQUITINATION; WILD TYPE;

ACETYLATION; ANIMALS; BENZOQUINONES; CELL LINE, TUMOR; HSP90 HEAT-SHOCK PROTEINS; HUMANS; LACTAMS, MACROCYCLIC; MICE; MICE, KNOCKOUT; MOLECULAR CHAPERONES; MUTANT PROTEINS; NEOPLASMS; PROTO-ONCOGENE PROTEINS C-MDM2; TUMOR SUPPRESSOR PROTEIN P53; UBIQUITIN-PROTEIN LIGASES; UBIQUITINATION;

MUS;

EID: 79956017927     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-10-0534     Document Type: Article

References (35)

1. Midgley CA, Lane DP. p53 protein stability in tumour cells is not determined by mutation but is dependent on Mdm2 binding. Oncogene 1997;15:1179-89. (Pubitemid 27429621)
2. Lang GA, Iwakuma T, Suh YA, Liu G, Rao VA, Parant JM, et al. Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell 2004;119:861-72. (Pubitemid 40017691)
3. Olive KP, Tuveson DA, Ruhe ZC, Yin B, Willis NA, Bronson RT, et al. Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell 2004;119:847-60. (Pubitemid 40017690)
4. Terzian T, Suh YA, Iwakuma T, Post SM, Neumann M, Lang GA, et al. The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss. Genes Dev 2008;22:1337-44. (Pubitemid 351717524)
5. Cheng TH, Cohen SN. Human MDM2 isoforms translated differentially on constitutive versus p53-regulated transcripts have distinct functions in the p53/MDM2 and TSG101/MDM2 feedback control loops. Mol Cell Biol 2007;27:111-9. (Pubitemid 46013237)
6. Bossi G, Lapi E, Strano S, Rinaldo C, Blandino G, Sacchi A. Mutant p53 gain of function: reduction of tumor malignancy of human cancer cell lines through abrogation of mutant p53 expression. Oncogene 2006;25:304-9. (Pubitemid 43083692)
7. Yan W, Liu G, Scoumanne A, Chen X. Suppression of inhibitor of differentiation 2, a target of mutant p53, is required for gain-offunction mutations. Cancer Res 2008;68:6789-96.
8. Blagosklonny MV, Toretsky J, Bohen S, Neckers L. Mutant conformation of p53 translated in vitro or in vivo requires functional HSP90. Proc Natl Acad Sci U S A 1996;93:8379-83. (Pubitemid 26269566)
9. King FW, Wawrzynow A, Höhfeld J, Zylicz M. Co-chaperones Bag-1, Hop and Hsp40 regulate Hsc70 and Hsp90 interactions with wild-type or mutant p53. EMBO J 2001:20:6297-305. (Pubitemid 33078703)
10. Whitesell L, Sutphin PD, Pulcini EJ, Martinez JD, Cook PH. The physical association of multiple molecular chaperone proteins with mutant p53 is altered by Geldanamycin, an hsp90-binding agent. Mol Cell Biol 1998;18:1517-24. (Pubitemid 28100917)
11. Chen J, Wu X, Lin J, Levine AJ. mdm-2 inhibits the G1 arrest and apoptosis functions of the p53 tumor suppressor protein. Mol Cell Biol 1996;16:2445-52. (Pubitemid 26123766)
12. Becker K, Marchenko ND, Maurice M, Moll UM. Hyperubiquitylation of wild-type p53 contributes to cytoplasmic sequestration in neuroblastoma. Cell Death Differ 2007;14:1350-60. (Pubitemid 46965264)
13. Buschmann T, Minamoto T, Wagle N, Fuchs SY, Adler V, Mai M, et al. Analysis of JNK, Mdm2 and p14(ARF) contribution to the regulation of mutant p53 stability. J Mol Biol 2000;295:1009-21.
14. Lukashchuk N, Vousden KH. Ubiquitination and degradation of mutant p53. Mol Cell Biol 2007;27:8284-95. (Pubitemid 350234240)
15. Nie LH, Sasaki M, Maki CG. Regulation of p53 nuclear export through sequential changes in conformation and ubiquitination. J Biol Chem 2007;282:14616-25. (Pubitemid 47100427)
16. Marchenko ND, Hanel W, Li D, Becker K, Reich N, Moll UM. Stress-mediated nuclear stabilization of p53 is regulated by ubiquitination and importin-alpha3 binding. Cell Death Differ 2010;17:255-67.
17. Kamijo T, Weber JD, Zambetti G, Zindy F, Roussel MF, Sherr CJ. Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. P Natl Acad Sci U S A 1998;95:8292-7. (Pubitemid 28326106)
18. Stott FJ, Bates S, James MC, McConnell BB, Starborg M, Brookes S, et al. The alternative product from the human CDKN2A locus, p14 (ARF), participates in a regulatory feedback loop with p53 and MDM2. EMBO J 1998;17:5001-14.
19. Song H, Hollstein M, Xu Y. P53 gain-of-function cancer mutants induce genetic instability by inactivating ATM. Nat Cell Biol 2007;9:573-80. (Pubitemid 46696539)
20. Tang Y, Zhao WH, Chen Y, Zhao YM, Gu W. Acetylation is indispensable for p53 activation. Cell 2008;133:612-26. (Pubitemid 351636297)
21. Stommel JM, Wahl GM. Accelerated MDM2 auto-degradation induced by DNA-damage kinases is required for p53 activation. EMBO J 2004;23:1547-56. (Pubitemid 38579515)
22. Whitesell L, Lindquist SL. HSP90 and the chaperoning of cancer. Nat Rev Cancer 2005;5:761-7.
23. Kamal A, Thao L, Sensintaffar J, Zhang L, Boehm MF, Fritz LC, et al. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 2003;425:407-10. (Pubitemid 37187270)
24. Peng YH, Chen LH, Li CG, Lu WG, Chen JD. Inhibition of MDM2 by hsp90 contributes to mutant p53 stabilization. J Biol Chem 2001;276:40583-90.
25. Xiao XZ, Zuo XX, Davis AA, McMillan DR, Curry BB, Richardson JA, et al. HSF1 is required for extra-embryonic development, postnatal growth and protection during inflammatory responses in mice. EMBO J 1999;18:5943-52. (Pubitemid 29515671)
26. Trepel J, Mollapour M, Giaccone G, Neckers L. Targeting the dynamic HSP90 complex in cancer. Nat Rev Cancer 2010;10:537-49.
27. Whitesell L, Sutphin P, An WG, Schulte T, Blagosklonny MV, Neckers L. Geldanamycin-stimulated destabilization of mutated p53 is mediated by the proteasome in vivo. Oncogene 1997;14:2809-16.
28. Lin K, Rockliffe N, Johnson GG, Sherrington PD, Pettitt AR. Hsp90 inhibition has opposing effects on wild-type and mutant p53 and induces p21 expression and cytotoxicity irrespective of p53/ATM status in chronic lymphocytic leukaemia cells. Oncogene 2008;27:2445-55. (Pubitemid 351521099)
29. Ayrault O, Godeny MD, Dillon C, Zindy F, Fitzgerald P, Roussel MF, et al. Inhibition of Hsp90 via 17-DMAG induces apoptosis in a p53- dependent manner to prevent medulloblastoma. P Natl Acad Sci U S A 2009;106:17037-42.
30. Xu WP, Marcu M, Yuan XT, Mimnaugh E, Patterson C, Neckers L. Chaperone-dependent E3 ubiquitin ligase CHIP mediates a degradative pathway for c-ErbB2 Neu. P Natl Acad Sci U S A 2002;99:12847-52.
31. Dickey CA, Kamal A, Lundgren K, Klosak N, Bailey RM, Dunmore J, et al. The high-affinity HSP90-CHIP complex recognizes and selectively degrades phosphorylated tau client proteins. J Clin Invest 2007;117:648-58. (Pubitemid 46348523)
32. Esser C, Scheffner M, Hohfeld J. The chaperone-associated ubiquitin ligase CHIP is able to target p53 for proteasomal degradation. J Biol Chem 2005;280:27443-8. (Pubitemid 41040787)
33. Muller P, Hrstka R, Coomber D, Lane DP, Vojtesek B. Chaperone-dependent stabilization and degradation of p53 mutants. Oncogene 2008;27:3371-83. (Pubitemid 351769319)
34. Morishima Y, Wang AM, Yu ZG, Pratt WB, Osawa YC, Lieberman AP. CHIP deletion reveals functional redundancy of E3 ligases in promoting degradation of both signaling proteins and expanded glutamine proteins. Hum Mol Genet 2008;17:3942-52. (Pubitemid 352762855)
35. Adorno M, Cordenonsi M, Montagner M, Dupont S, Wong C, Hann B, et al. A mutant-p53/Smad complex opposes p63 to empower TGF beta-induced metastasis. Cell 2009;137:87-98.